317 related articles for article (PubMed ID: 21300618)
61. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
[TBL] [Abstract][Full Text] [Related]
62. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer.
Onuki M; Matsumoto K; Satoh T; Oki A; Okada S; Minaguchi T; Ochi H; Nakao S; Someya K; Yamada N; Hamada H; Yoshikawa H
Cancer Sci; 2009 Jul; 100(7):1312-6. PubMed ID: 19432906
[TBL] [Abstract][Full Text] [Related]
63. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer.
Nindl I; Rindfleisch K; Lotz B; Schneider A; Dürst M
Int J Cancer; 1999 Jul; 82(2):203-7. PubMed ID: 10389753
[TBL] [Abstract][Full Text] [Related]
64. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grades 1 or worse among 4215 Chinese women in a population-based study.
Zhang R; Velicer C; Chen W; Liaw KL; Wu EQ; Liu B; Cui JF; Belinson JL; Zhang X; Shen GH; Chen F; Qiao YL
Cancer Epidemiol; 2013 Dec; 37(6):939-45. PubMed ID: 24210584
[TBL] [Abstract][Full Text] [Related]
65. Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.
Syrjänen K; Shabalova I; Sarian L; Naud P; Longatto-Filho A; Derchain S; Kozachenko V; Zakharchenko S; Roteli-Martins C; Nerovjna R; Kljukina L; Tatti S; Branovskaja M; Branca M; Grunjberga V; Erzen M; Juschenko A; Serpa Hammes L; Podistov J; Costa S; Syrjänen S; ;
Eur J Gynaecol Oncol; 2012; 33(1):5-14. PubMed ID: 22439398
[TBL] [Abstract][Full Text] [Related]
66. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis.
Ogembo RK; Gona PN; Seymour AJ; Park HS; Bain PA; Maranda L; Ogembo JG
PLoS One; 2015; 10(4):e0122488. PubMed ID: 25875167
[TBL] [Abstract][Full Text] [Related]
67. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.
Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Katki H; Cheung L; Wacholder S; Burk RD
J Natl Cancer Inst; 2010 Mar; 102(5):315-24. PubMed ID: 20157096
[TBL] [Abstract][Full Text] [Related]
68. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
69. Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts.
Syrjänen K; Shabalova I; Naud P; Kozachenko V; Derchain S; Zakharchenko S; Roteli-Martins C; Nerovjna R; Longatto-Filho A; Kljukina L; Tatti S; Branovskaja M; Hammes LS; Branca M; Grunjberga V; Erzen M; Sarian LO; Juschenko A; Costa S; Podistov J; Syrjänen S;
Int J Gynecol Cancer; 2009 Jul; 19(5):934-42. PubMed ID: 19574788
[TBL] [Abstract][Full Text] [Related]
70. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
71. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
Simonella LM; Lewis H; Smith M; Neal H; Bromhead C; Canfell K
BMC Infect Dis; 2013 Mar; 13():114. PubMed ID: 23452957
[TBL] [Abstract][Full Text] [Related]
72. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
[TBL] [Abstract][Full Text] [Related]
73. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
[TBL] [Abstract][Full Text] [Related]
74. [Association between high-risk human papillomavirus DNA load and different histological grades of cervical neoplasia].
Zhao FH; Hu SY; Wang SM; Chen F; Zhang X; Zhang WH; Pan QJ; Qiao YL
Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Jul; 43(7):565-70. PubMed ID: 19954065
[TBL] [Abstract][Full Text] [Related]
75. Analysis of the prevalence of human papillomavirus and abnormal anal cytology in women at risk.
Lopez-Cavanillas B; G Benitez C; Serrano M; Sendagorta E; Hernandez A; Bartha JL
J Obstet Gynaecol; 2021 Oct; 41(7):1139-1144. PubMed ID: 33459109
[TBL] [Abstract][Full Text] [Related]
76. Different detectability of high-risk HPV in smears from incident and prevalent high-grade squamous intraepithelial lesions of the cervix.
Schneider A; Zahm DM; Greinke C; Kirchmayr R; Nindl I
Gynecol Oncol; 1997 Jun; 65(3):399-404. PubMed ID: 9190964
[TBL] [Abstract][Full Text] [Related]
77. Human papillomavirus infections among women with cervical lesions and cervical cancer in Eastern China: genotype-specific prevalence and attribution.
Zhang L; Bi Q; Deng H; Xu J; Chen J; Zhang M; Mu X
BMC Infect Dis; 2017 Jan; 17(1):107. PubMed ID: 28143439
[TBL] [Abstract][Full Text] [Related]
78. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
[TBL] [Abstract][Full Text] [Related]
79. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
[TBL] [Abstract][Full Text] [Related]
80. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
